Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database

Key Points

• This research aims to examine the ocular toxicity associated with anti-CD20 monoclonal antibodies using the FAERS database.
• Analyzed adverse event reports from the FAERS database
• Identified reports related to anti-CD20 monoclonal antibodies
• Classified and evaluated ocular adverse events
• 86% of ocular adverse events were linked to a specific antibody
• Ofatumumab contributed 11% and obinutuzumab 2% of reports
• Over half of ocular adverse events occurred within 15 days of treatment initiation
• All four anti-CD20 agents indicated signals for ocular infections, suggesting a potential class effect.